In 2002, Frederic MASCHA took the opportunity of a first acquisition, Lysanxia® (prazepam), a psychiatric drug from Pfizer, to found a pharmaceutical company called LynaPharm, through a joint venture with the Italian pharmaceutical group, Sigma-Tau.
Later on, LynaPharm acquired the rights of Anafranil® (clomipramine), an antidepressant drug from Novartis, and Synedil® (sulpiride), for psychotic disorders from Astellas.
Frederic MASCHA and his holding company, Juvise, sold their LynaPharm shares to the Sigma-Tau group in 2008 to create Juvise Pharmaceuticals.
Following the sale of LynaPharm laboratories in 2008, Frederic MASCHA created Juvise Pharmaceuticals.
Juvise Pharmaceuticals is a specialty pharmaceutical company manufacturing and marketizing its own branded pharmaceutical specialties – acquired from large pharmaceutical companies – in 75 countries in the world.
Juvise Pharmaceuticals currently markets 9 specialty pharmaceutical products, essential in the treatment of cancer, cardiovascular, neurologic-psychiatric and rheumatic disorders: Arimidex® (anastrozole), Casodex® (bicalutamide), Esidrex® (hydrochlorothiazide), Sintrom® (acenocoumarol), Digoxin-Juvise® (digoxin), Entumin® (clotiapine), Insidon® (opipramol), Extovyl® (betahistine mesilate) and Lumirelax® (methocarbamol).
creates Juvisé Pharmaceuticals